Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Impact of fibrinogen levels and modified Glasgow prognostic score on survival of stage III/N2 non-small cell lung cancer patients treated with neoadjuvant therapy and radical resection

Fig. 1

Comparison of survival outcomes for the DFS (A) and OS (B) in surgically treated stage III/N2 NSCLC patients after neoadjuvant therapy according to fibrinogen levels (Median DFS and OS were 15.97 vs 32.37 months and 28.17 vs 60.9 months, respectively; HR 0.653, 95% CI 0.374–1.139, p = 0.130; and HR 0.562, 95% CI 0.315–1.004, p = 0.048). Fibrinogen cut off value was 400 mg/dL

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us